Skip to main content

Table 4 HPV positivity, genotype, and HPV test by stage of triage and histology

From: 5-type HPV mRNA versus 14-type HPV DNA test: test performance, over-diagnosis and overtreatment in triage of women with minor cervical lesions

 

HPV DNA

5-type-mRNA

  

HPVNeg.

HPV 16

HPV 18

HPV other

 

HPVNeg.

HPV 16

HPV 18

HPV other

Stages of triage

N

%

%

%

%

N

%

%

%

%

At triagea

564

69.7

8.5

2.3

19.5

564

81.4

8.7

2.1

7.8

Recommended biopsyb

141

 

28.4

8.5

63.1

92

 

45.7

10.9

43.5

Had biopsyc

105

 

36.2

7.6

56.2

77

 

51.9

9.1

39.0

By histology

N

 

%

%

%

N

 

%

%

%

Normal/CIN1

67

 

26.9

7.5

65.7

47

 

44.7

8.5

46.8

CIN2

23

 

39.1

13.0

47.8

15

 

53.3

20.0

26.7

CIN3

14

 

71.4

0.0

28.6

14

 

71.4

0.0

28.6

Sq. cell carcinoma

1

 

0.0

0.0

100

1

 

0.0

0.0

100

  1. HPV DNA other HPV type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68
  2. 5-type-mRNA other HPV type 31, 33, and 45
  3. CIN cervical intraepitelial neoplasi
  4. aThe Norwegian cervical cancer screening program recommended triage 6 to 12 months after the index ASC-US/LSIL
  5. bWomen with either a positive HPV DNA or a positive HPV mRNA test are recommended biopsy
  6. cIn total 141 women were recommended colposcopy by the DNA test, and 105 (74 %) met for biopsy. Out of the 92 women scheduled for biopsy by the 5-type mRNA test, 77 (84 %) made a visit (p = 0.12)